1. Home
  2. WBX vs VERU Comparison

WBX vs VERU Comparison

Compare WBX & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wallbox N.V.

WBX

Wallbox N.V.

HOLD

Current Price

$3.23

Market Cap

50.6M

ML Signal

HOLD

Logo Veru Inc.

VERU

Veru Inc.

HOLD

Current Price

$2.38

Market Cap

40.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WBX
VERU
Founded
2015
1971
Country
Spain
United States
Employees
696
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
50.6M
40.9M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
WBX
VERU
Price
$3.23
$2.38
Analyst Decision
Buy
Strong Buy
Analyst Count
4
2
Target Price
$4.75
$22.50
AVG Volume (30 Days)
19.0K
46.7K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$16,296,958.00
Revenue This Year
$18.10
N/A
Revenue Next Year
$94.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.23
$0.36
52 Week High
$7.83
$4.59

Technical Indicators

Market Signals
Indicator
WBX
VERU
Relative Strength Index (RSI) 61.85 47.53
Support Level $2.84 $2.13
Resistance Level $3.26 $2.67
Average True Range (ATR) 0.21 0.11
MACD 0.03 -0.00
Stochastic Oscillator 91.86 21.85

Price Performance

Historical Comparison
WBX
VERU

About WBX Wallbox N.V.

Wallbox NV is a smart electric vehicle charging and energy management company. It creates a smart charging system combining technology design that manages the communication between the user, vehicle, grid, building, and charger. The company designs, manufactures, and distributes faster, simpler EV charging solutions for residential, business, and public use. Its smart charging product portfolio includes Level 2 alternating current chargers for home and business applications and direct current fast chargers for public applications. The company has three reportable operating segments; Europe, Middle East and Asia (EMEA), its key revenue-generating segment, North America, and Asia-Pacific.

About VERU Veru Inc.

Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.

Share on Social Networks: